PROM1 and neoplasm: In an attempt to improve the delivery of TMZ at the tumor site and moreover to target the origin of the tumor initiation, that is, stem cells (SCs), Kim et al. prepared a dual-targeting immunoliposome carrying TMZ by using angiopep-2 (An2) and an anti-CD133 monoclonal antibody (CD133 mAb) for BBB transcytosis and specific delivery to GBM stem cells (GSCs), respectively [80].